In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovation

Set Alert for Innovation

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

The quality of clinical trials and data analysis have come a long way in the past 10 years – and even in the past three, says Christian Hebenstreit of Medidata, the cloud-based platform that supports pharma and medtech companies through clinical studies ahead of their commercial uptake. The buzzwords of the fairly recent past are now being applied as real tools in the clinical trials arena, and look set to transform the sector.

Clinical Trials Innovation Artificial Intelligence
Advertisement

Latest From Innovation

Microbiome Drug Development: An Investigation Into Challenges And Innovative Pipeline Approaches

The discovery and deep investigation of the microbiome has been one of the most cutting-edge advances in biomedical research of recent times, but as the science moves forward new hurdles are emerging for microbiome therapies.

Innovation Gastrointestinal

Drug Delivery Trends Across The Biopharma Pipeline

Exploring route of administration, mode of action, clinical trial, and therapy area trends across the biopharma pipeline.

Innovation Research and Development Strategies

TRD Societal Cost Can Sway US Payer On VNS Coverage Decision

LivaNova is counting on CMS paying more than lip service to the value-based agenda as it assesses coverage decisions for Vagus Nerve Stimulation (VNS) for the treatment of resistant depression over the coming months. In many ways it is a test for both parties.

Innovation Reimbursement

True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal

Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

Clinical Trials Innovation

Treatments Beyond Treatment: ASCO's Expanding Vision of Cancer Care

Cancer's chief professional practice organization, the American Society of Clinical Oncology (ASCO), is working to transform the post-treatment pathway for survivors of cancer. It is part of an overall movement in the cancer community emphasizing the importance of making current treatments work better for more patients. 

Cancer Innovation

NASH: Flying The Plane While Building It

Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.
Liver & Hepatic Innovation
See All
UsernamePublicRestriction

Register